Support for Oxbryta from Day One

The GBT Source Care Team includes:

Care Coordinators who will:

Help you (or your authorized Caregiver) understand your insurance benefits
Review financial assistance programs for which you may be eligible

A Nurse Support Team who is available to:

Answer questions you (or your Authorized Caregiver) may have about Oxbryta
Provide resources and personalized support to help you start and stay on treatment as prescribed by your healthcare provider^*

The Nurse Support Team is there to support product adherence and not replace a patient’s treatment plan. They do not provide medical advice or case management services.

Learn More About GBT Source Solutions

If you (or your Authorized Caregiver) have additional questions or want more information about GBT Source, please visit the GBT Source website

Find a Specialist

Find a hematologist in your area.

Society of Hemotology

Find Support Organizations

Search community-based and national organizations offering support and resources that may be available in your area. These organizations are independent and not affiliated with GBT Source.^*

These resources are meant to be informational only and are not intended to replace medical advice.

Download the GBT Source Patient Brochure

Your guide to Oxbryta treatment support and how to get started with GBT Source.

GBT Source Solutions Brochure thumbnail

GBT Source Solutions Brochure

To learn more, call

(833) 428-4968

PRESS 1 TO SPEAK WITH A REPRESENTATIVE
(833-GBT-4YOU) M-F, 8am-8pm ET

INDICATION

What is OXBRYTA?

OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 12 years of age and older.

It is not known if OXBRYTA is safe and effective in children below 12 years of age.

This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Do not take OXBRYTA if you have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.

If you are receiving exchange transfusions, talk to your healthcare provider about possible difficulties with the interpretation of certain blood tests when taking OXBRYTA.

Before taking OXBRYTA, tell your healthcare provider about all of your medical conditions, including if you:

have liver problems
are pregnant or plan to become pregnant. It is not known if OXBRYTA can harm your unborn baby
are breastfeeding or plan to breastfeed. It is not known if OXBRYTA can pass into your breastmilk and if it can harm your baby. Do not breastfeed during treatment with OXBRYTA and for at least 2 weeks after the last dose

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work.

What are the possible side effects of OXBRYTA?

OXBRYTA can cause serious side effects, including:

Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:

rash
hives

shortness of breath
swelling of the face

The most common side effects of OXBRYTA include:

headache
diarrhea
stomach (abdominal) pain
nausea

tiredness
rash
fever

These are not all the possible side effects of OXBRYTA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).

Keep OXBRYTA and all medicines out of the reach of children.

Oxbryta is a registered trademark, and GBT Source and GBT Source Solutions are trademarks of Global Blood Therapeutics, Inc. All other trademarks are the property of their respective owners.

© 2021 Global Blood Therapeutics, Inc. All Rights Reserved. P-VOX-US-00098 v4

This site is intended for residents of the United States, Puerto Rico, and US territories.